Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.1 1.97

Buy Sell

Overview

Share price change

24h

Current

Min

3.09

Max

3.13

Key metrics
By Trading Economics
Income	-511K -28M
Sales	-13M 2.6M
EPS	-0.47
Profit margin	-1,077.401
Employees	141
EBITDA	1.9M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+448.39% upside

Dividends
By Acuity
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-50M 184M
Previous open	1.13
Previous close	3.1

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lip 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Saturday's session, building on Friday's gains. The price movement aligns with Ethereum's upward trend.

25 lip 2026, 23:42 UTC

Personal Income MoM Data Release on July 30, 2026, Forecasts Modest Growth Amid Ongoing Market Volatility and Geopolitical Concerns.

25 lip 2026, 23:42 UTC

U.S. Personal Spending Expected to Rise 0.4% in June Amid Inflation and Geopolitical Tensions Impacting Consumer Behavior

25 lip 2026, 23:42 UTC

Market Awaits Key PCE Price Index Data on July 30, 2026, Amid Rising Inflation Concerns and Potential Impact on Federal Reserve Policy.

25 lip 2026, 23:42 UTC

South Korea's exports surge 70.9% in June, with August release expected to reveal continued growth amid cautious investor sentiment due to inflation and geopolitical tensions.

25 lip 2026, 23:42 UTC

U.S. GDP Price Index Set for 3.7% Increase Amid Cautious Optimism and Inflation Concerns Ahead of Key Federal Reserve Policy Decisions.

25 lip 2026, 23:42 UTC

Traders Brace for PCE Price Index Release Amid Geopolitical Tensions and Inflation Concerns, Anticipating 0.4% Increase

25 lip 2026, 23:42 UTC

Core PCE Price Index MoM Release on July 30, 2026, Expected to Show Modest 0.1% Increase Amid Inflation Concerns and Market Sensitivity.

25 lip 2026, 23:42 UTC

U.S. Q2 2026 GDP Growth Rate Release Expected at 2.3% Amid Positive Economic Sentiment and Geopolitical Concerns

25 lip 2026, 23:32 UTC

S&P/Case-Shiller Home Price Index Set for July Release Amidst Cautious Market Sentiment and Inflation Concerns

25 lip 2026, 23:32 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is under scrutiny as analysts anticipate continued deficits amid rising imports and geopolitical tensions.

25 lip 2026, 23:31 UTC

"Cryptocurrency Gains Amid Geopolitical Tensions; European Stocks Shift and Fed's Rate Decision Looms"

25 lip 2026, 23:31 UTC

Cryptocurrency gains amid European market reassessment and bond turmoil, as investors brace for the Fed's interest rate decision and Japan's fiscal policy shift.

25 lip 2026, 23:31 UTC

Bitcoin and Ethereum rise amid shifting European equity markets, Japan's fiscal policy changes, and looming Federal Reserve interest rate decision.

25 lip 2026, 23:31 UTC

Cryptocurrency prices rise as Bitcoin and Ethereum gain, while European equity markets face shifts and Japan's fiscal policy change looms ahead of the Federal Reserve's interest rate decision.

25 lip 2026, 23:24 UTC

Mexico's Q2 GDP Growth Rate Release on July 30 Sparks Cautious Optimism Amid Strong Services PMI Performance.

25 lip 2026, 23:24 UTC

Brazil's Unemployment Rate Expected to Remain Stable or Improve in June 2026 Amid Cautious Optimism and Economic Recovery Concerns

25 lip 2026, 23:13 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Sparks Caution Amid Geopolitical Tensions and Trade Tariff Concerns.

25 lip 2026, 23:13 UTC

Japan's Industrial Production MoM data for June 2026 set to release on July 30, with a modest increase of 0.7% anticipated amid mixed economic sentiment and rising inflation concerns.

25 lip 2026, 23:13 UTC

Germany's Inflation Rate Release on July 30, 2026: Market Anticipates Continued Pressure Amid Mixed Economic Signals.

25 lip 2026, 23:13 UTC

Japan's Retail Sales Expected to Rise 2.8% YoY Amid Concerns Over Consumer Spending and Economic Recovery Challenges

25 lip 2026, 23:13 UTC

Germany's July Inflation Rate Expected to Rise 0.7% Amid Mixed Economic Sentiment and Rising Oil Prices

25 lip 2026, 23:03 UTC

Wholesale Inventories MoM Advance Data Set for Release Amid Mixed Economic Sentiment and Geopolitical Tensions, Forecasting 0.2% Increase.

25 lip 2026, 23:03 UTC

U.S. Goods Trade Balance Release Expected to Show $98 Billion Deficit Amid Tariff Concerns and Inflation Pressures

25 lip 2026, 23:03 UTC

U.S. Retail Inventories Ex Autos Data Release on July 28, Amid Weakening Consumer Spending and Inflation Concerns

25 lip 2026, 23:01 UTC

Avalanche continues to trade higher, reflecting strong performance since Friday's close. Earlier, it peaked over 8%, remaining above its 20-day moving average.

25 lip 2026, 22:51 UTC

Japan's June 2026 unemployment rate forecast at 2.5% amid rising inflation concerns and market volatility ahead of release on July 30, signaling mixed investor sentiment.

25 lip 2026, 22:42 UTC

Durable Goods Orders Report on July 27, 2026 Expected to Show Recovery Amidst Market Volatility and Geopolitical Tensions.

25 lip 2026, 22:42 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.9% in June Amid Cautious Optimism and External Economic Pressures

25 lip 2026, 22:42 UTC

Mortgage Rates Hit 6.69% Amid Rising Treasury Yields and Inflation Concerns, Influencing Real Estate Market Dynamics

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

448.39% upside

12 Months Forecast

Average 17 USD 448.39%

High 25 USD

Low 8 USD

Based on 6 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.